Radiation to Metastases Cuts Cancer Progression Risk in Half in Phase II Trial
Adding targeted radiation to standard therapy reduced progression by 46% across multiple cancer types in the EXTEND trial.
Summary
The EXTEND trial tested whether targeting individual metastases with radiation therapy, on top of standard drug treatment, could slow cancer progression in patients with a limited number of metastases (1–5). Across 334 patients and multiple cancer types, adding this metastasis-directed therapy cut the risk of cancer progression nearly in half over a median follow-up of 53 months. Benefits were clearest in pancreatic, prostate, and mixed-tumor patients. The trial also found that a blood-based marker called circulating tumor DNA could predict outcomes, and that the treatment appeared to trigger a broader immune response — potentially explaining why it works beyond just destroying visible tumors.
Detailed Summary
For patients whose cancer has spread to only a few sites — a state called oligometastatic disease — a critical question is whether destroying those individual metastases can meaningfully change the disease course. The EXTEND trial, a multicenter randomized phase II study conducted primarily through MD Anderson Cancer Center and collaborating institutions, set out to answer this with rigorous evidence across multiple cancer types.
Researchers enrolled patients with 1–5 metastases across six tumor-type baskets: breast, pancreas, kidney, two prostate groups, and a mixed 'Other' basket. A total of 334 patients were analyzed per protocol after randomization to either metastasis-directed therapy (MDT) plus standard of care (SOC) or SOC alone (166 vs. 168). Radiotherapy was used for 98% of targeted metastases, and participants were followed for a median of 53 months.
The headline result was striking: adding MDT to SOC reduced the hazard of progression by 46% overall (HR 0.54, 95% CI 0.41–0.72, p<0.001). Even after excluding the prostate baskets — which had unique characteristics — the benefit held (HR 0.60, 95% CI 0.40–0.89). Individual basket analyses showed clear PFS superiority for pancreas, prostate, and 'Other' tumor types, while breast and kidney baskets produced inconclusive results.
Two translational findings add important depth. First, detectable circulating tumor DNA (ctDNA) at enrollment predicted shorter PFS and survival, while ctDNA clearance at three months post-enrollment correlated with improved survival — pointing toward a liquid biopsy tool for refining patient selection. Second, systemic immune activation was most pronounced in the baskets that demonstrated PFS superiority, suggesting MDT may work partly by stimulating anti-tumor immunity beyond the irradiated site.
The trial provides phase II-level evidence supporting MDT for oligometastatic disease and identifies specific tumor histologies for phase III validation. Caveats include the basket trial design limiting power within individual cancer types, and this summary being based on the published abstract.
Key Findings
- Adding radiation to metastatic sites reduced progression risk by 46% across cancer types (HR 0.54, p<0.001).
- Pancreas, prostate, and mixed-tumor baskets showed clear PFS benefit; breast and kidney results were inconclusive.
- Detectable ctDNA at baseline predicted worse survival; ctDNA clearance at 3 months correlated with improved outcomes.
- Systemic immune activation was strongest in tumor types that responded best, suggesting an abscopal-like mechanism.
- Radiotherapy was used as the metastasis-directed therapy in 98% of treated metastatic lesions.
Methodology
EXTEND was a multicenter randomized phase II basket trial enrolling patients with 1–5 metastases across six tumor-histology groups from 2018–2023. Patients were randomized to MDT plus SOC vs. SOC alone, with progression-free survival as the primary endpoint analyzed in per-protocol sets. Exploratory endpoints included ctDNA dynamics and immune profiling.
Study Limitations
This is a phase II trial with basket-level analysis, meaning individual tumor-type subgroups may be underpowered to draw definitive conclusions. The breast and kidney cancer baskets did not show statistically clear benefit. Additionally, this summary is based solely on the published abstract, as the full text is not open access.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.